There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association.
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens / Cozzi-lepri, A; Zangerle, R; Machala, L; Zilmer, K; Ristola, M; Pradier, C; Kirk, O; Sambatakou, H; Fätkenheuer, G; Yust, I; Schmid, P; Gottfredsson, M; Khromova, I; Jilich, D; Flisiak, R; Smidt, J; Rozentale, B; Radoi, R; Losso, M. H; Lundgren, J. D; Mocroft, A; Eurosida Study, Group; Castagna, A; Lazzarin, A. - In: HIV MEDICINE. - ISSN 1464-2662. - (2017). [Epub ahead of print] [10.1111/hiv.12557]
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
Castagna, AMembro del Collaboration Group
;Lazzarin, AMembro del Collaboration Group
2017-01-01
Abstract
There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
